- Suppression of HIV-1 replication by microRNA effectorsChristine Chable-Bessia
Institut de Génétique Humaine CNRS UPR1142, Laboratoire de Virologie Moleculaire, Montpellier, France
Retrovirology 6:26. 2009..Interestingly, knockdown of RCK/p54 or DGCR8 resulted in virus reactivation in PBMCs isolated from HIV infected patients treated with suppressive HAART...
- Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patientsGael Petitjean
Laboratoire de Virologie, Hopital Lapeyronie, avenue du Doyen Gaston Giraud, 34295 Montpellier, France
Retrovirology 4:60. 2007..The presence of HIV-1 preintegration reservoir was assessed in an in vitro experimental model of latent HIV-1 infection, and in patients treated or not with highly active antiretroviral therapy (HAART)...
- [Antiretroviral therapies: strategic perspectives for the future]J Reynes
Service des Maladies Infectieuses et Tropicales, , CHU de Montpellier, France
Med Trop (Mars) 67:367. 2007
- TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes
Hopital Gui de Chauliac, CHU Montpellier, France
AIDS Patient Care STDS 21:533-43. 2007..In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial...
- Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 studyRoland Landman
Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
J Antimicrob Chemother 64:118-25. 2009..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
- Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infectionPierre Portales
Laboratoire d'Immunologie, , Service des Maladies Infectieuses et Tropicales, , Montpellier, France
AIDS 17:505-11. 2003..647; P= 0.017). CONCLUSION: The pre-therapeutic percentage of perforin-positive T cells might be a predictive marker of the virological response to IFNalpha in HIV-1-infected patients...
- Diagnostic approaches to imported schistosomal myeloradiculopathy in travelersA Makinson
Department of Infectious Diseases, University Hospital, Montpellier, F-34295 Montpellier, France
Neurology 71:66-7. 2008
- Pregnancy may be followed by an inflexion of the immune reconstitution in HIV-infected women who receive antiretroviral drugs before conceptionV Le Moing
Centre Hospitalier Universitaire, Montpellier, France
HIV Med 9:897-900. 2008..Whether pregnancy has an impact on the evolution of CD4 cell counts in women treated with highly potent antiretrovirals before conception remains largely unknown...
- Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patientDidier Bessis
Service de Dermatologie Phlébologie, CHU Montpellier, Hopital Saint Eloi, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
Eur J Dermatol 12:99-102. 2002..We review the literature on previously reported cases of cutaneous necrosis following standard or pegylated IFN-alpha injection and discuss the different pathophysiological mechanisms that might be involved...
- Molecular diagnosis of culture-negative cerebral nocardiosis due to Nocardia abscessusHelene Marchandin
Laboratoire de Bacteriologie, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
Diagn Microbiol Infect Dis 55:237-40. 2006..The patient is alive and well on imipenem and doxycycline therapy, 14 months after onset...
- Reasons for early abacavir discontinuation in HIV-infected patientsHelene Peyriere
Pharmacovigilance Center, Lapeyronie Hospital, Montpellier, France
Ann Pharmacother 37:1392-7. 2003..To determine incidence of and reasons for discontinuation of abacavir within the first 6 months of therapy...
- Efficacy of ceftriaxone and doxycycline in the treatment of early syphilisK C Psomas
Departement des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier Cedex, France
Med Mal Infect 42:15-9. 2012..An increase of syphilis cases has been recorded in the past few decades, especially among HIV-infected patients. These patients often present with concomitant primary and secondary lesions or extensive presentations of syphilis...
- CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progressionJ Reynes
Service des Maladies Infectieuses et Tropicales, , Montpellier, France
AIDS 15:1627-34. 2001..Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density...
- The fusion inhibitor enfuvirtide in recent antiretroviral strategiesAlain Makinson
Infectious Diseases Department, Montpellier University Hospital, CHU Montpellier, France
Curr Opin HIV AIDS 4:150-8. 2009..The purpose of this review is to discuss recent pharmacological, virological, and clinical data that concern enfuvirtide usage in different antiretroviral combinations...
- Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivoPierre Portales
Laboratoire d'Immunologie, , the Service des Maladies Infectieuses et Tropicales, , Montpellier, France
AIDS 17:495-504. 2003....
- [Ocular bartonellosis in an HIV-HVC coinfected patient]C Merle De Boever
Service Maladies Infectieuses et Tropicales, CHU de Montpellier, 80 avenue Augustin Flèche, Montpellier, France
Med Mal Infect 38:504-6. 2008..Nuclear magnetic resonance revealed a retrobulbar neuritis. Confirmation was given by blood tests positive for B. henselae and the exclusion of other causes of neuroretinitis with biological data. Doxycycline cured the disease rapidly...
- Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's diseaseAlain Makinson
Infectious Diseases Department, Gui de Chauliac Hospital, CHU Montpellier, France
Eur J Haematol 78:358-60. 2007..This unrecorded strategy is discussed...
- Renal tubular dysfunction associated with tenofovir therapy: report of 7 casesHelene Peyriere
Department of Medical Pharmacology, Lapeyronie Hospital, CHU Montpellier, France
J Acquir Immune Defic Syndr 35:269-73. 2004..In patients with low weight or mild preexisting renal impairment, regular monitoring of tubulopathy markers could lead to early detection of this dysfunction...
- [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir]Pierre Lochet
Service des Maladies Infectieuses et Tropicales, , CHU Montpellier, Montpellier, France
Therapie 60:175-81. 2005..6; p = 0.03). Frequency of abnormal proteinuria was 22%. CONCLUSION: Creatinine clearance, phosphataemia, proteinuria and glycosuria should be closely monitored in patients receiving tenofovir therapy...
- Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20Anne Genevieve Marcelin
Pitie Salpetriere Hospital, Paris, France
AIDS 18:1340-2. 2004..Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required...
- Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle
Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
HIV Clin Trials 7:86-96. 2006..g., ENF) for triple-class-experienced patients...
- Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeksBenoit Trottier
Clinique Médicale l Actuel, Montreal, Quebec, Canada
J Acquir Immune Defic Syndr 40:413-21. 2005..The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients...
- The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5 densityThierry Vincent
J Acquir Immune Defic Syndr 43:377-8. 2006
- Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adultsDirk Schurmann
Charite Universitatsmedizin, Berlin, Germany
AIDS 21:1293-9. 2007..To determine antiviral activity, pharmacokinetic properties, and safety of vicriviroc, an orally available CCR5 antagonist, as monotherapy in HIV-infected patients...
- Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapyAnne-Marie Fournier
, , 34295 Montpellier Cedex 5, France
AIDS 16:1755-60. 2002..These results pointed out that HIV-1 specific antibody secretion persisted in 11 out of 17 SR patients, suggesting persistent immune system activation by residual HIV-1 antigens...
- Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and AustraliaAdriano Lazzarin
Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Vita Salute University, Milan, Italy
N Engl J Med 348:2186-95. 2003....
- Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patientsEdouard Tuaillon
Laboratoire de Virologie, Hopital Lapeyronie, Montpellier, France
AIDS 21:2343-5. 2007..A lower number of HBs-SC was found in HBsAg-vaccinated patients compared with vaccinated controls...
- Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitroIsabelle Malet
Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
Antimicrob Agents Chemother 52:1351-8. 2008..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
- Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infectionYea-Lih Lin
, Centre National de la Recherche Scientifique, , , France
Proc Natl Acad Sci U S A 99:15590-5. 2002..These data explain why CCR5 density influences HIV-1 disease progression and underline the therapeutic interest of lowering CCR5 expression...
- [New antiretroviral treatment modalities]Jacques Reynes
Service des Maladies Infectieuses et Tropicales, UMR 145 VIH et Maladies Associées Hôpital Gui de Chauliac, 34295 Montpellier
Presse Med 34:1S23-30. 2005..For non-responders, thorough virological-pharmacological assessment is necessary, together with access to new molecules and new drug classes...
- Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
- Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008....
- Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment dispositionXiaoping Zhang
Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
Clin Pharmacol Ther 72:10-9. 2002....
- Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson
Chelsea and Westminster Hospital, London, United Kingdom
J Acquir Immune Defic Syndr 40:404-12. 2005....
- Low CD4+ T-cell surface CCR5 density as a cause of resistance to in vivo HIV-1 infectionJacques Reynes
J Acquir Immune Defic Syndr 34:114-6. 2003
- The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signallingYea-Lih Lin
, CNRS UPR1142, Montpellier, France
AIDS 20:1369-77. 2006..This observation sheds new light on the physiopathology of HIV infection, and opens new therapeutic opportunities targeting G alpha i signalling...
- Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)Christine Katlama
Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
AIDS 18:217-26. 2004..Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure...
- Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individualsJean-Michel Fondere
Laboratoire de Virologie, , avenue du Doyen Gaston Giraud, 34295 Montpellier, France
J Virol 78:10536-42. 2004..The ELISPOT approach to targeting the HIV-1-Ag-SCs could be a useful method for identifying latently HIV-1-infected CD4(+) T cells carrying replication-competent HIV-1 in patients responding to HAART...
- Vitamin E supplementation increases the expression of the CCR5 coreceptor in HIV-1 infected subjectsPierre Portales
Clin Nutr 23:1244-5. 2004
- Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype BBrigitte Montes
Department of Virology, University Hospital of Montpellier, Montpellier, France
J Acquir Immune Defic Syndr 35:329-36. 2004..CONCLUSION: Our results suggest that the genetic diversity of HIV-1 does not play a major role in the development of resistance to antiretroviral drugs...
- Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapyJacques Reynes
JAMA 291:46. 2004
- T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonistsThierry Vincent
, CNRS UPR 1142, Montpellier, France
J Acquir Immune Defic Syndr 38:305-9. 2005..In conclusion, we failed to demonstrate any impact of interindividual variability in T-cell surface CCR5 density on HCV infection, which would have argued against the use of CCR5 antagonists in HIV/HCV-coinfected subjects...
- Enumeration of latently infected CD4+ T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assayJean-Michel Fondere
Departement de Virologie Clinique, , 371 Avenue du Doyen Giraud, 34295 Montpellier edex 5, France
J Clin Virol 29:33-8. 2004..CONCLUSION: As each immunospot represents one HIV-1 antigen-secreting cell, the HIV-1 ELISPOT assay is a powerful to enumerate circulating CD4(+) T lymphocytes latently infected with HIV-1...
- CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strainsYea Lih Lin
Institut de Genetique Humaine, Montpellier, France
J Acquir Immune Defic Syndr 39:530-6. 2005..027). These data suggest that CXCR4 overexpression during the course of the disease in some patients could favor the emergence of X4 strains...
- Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapyJean-Michel Fondere
Virology Laboratory, Hospital Lapeyronie, INSERM U470, , Hospital A. Villeneuve, France
AIDS 17:2323-30. 2003....
- Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtideSharon Walmsley
University of Toronto, Toronto, Ontario, Canada
J Infect Dis 188:1827-33. 2003..Safety was unaffected by the presence of positive antibody at any time point or change in level of antibody. There was no evidence that enfuvirtide cross-reactive gp41 antibody affects the efficacy or safety of enfuvirtide...
- Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistanceBernard Masquelier
Département de Virologie et Immunologie, Hopital Pellegrin, Bordeaux, France
J Clin Virol 33:75-8. 2005..In HIV-infected patients on first-line antiretroviral therapy, the significance of intermittent viremia and their relationship with drug resistance remain unclear...
- Introduction of SARS in France, March-April, 2003Jean Claude Desenclos
Département Maladies Infectieuses, Institut de Veille Sanitaire, Saint Maurice, France
Emerg Infect Dis 10:195-200. 2004..Timely detection, isolation of probable case-patients, and quarantine of their contacts appear to have been effective in preventing the secondary spread of SARS in France...
- Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patientsJean-Michel Fondere
Laboratoire de Virologie, , Montpellier, France
J Acquir Immune Defic Syndr 35:114-9. 2004..We found that in AIDS patients, HIV-1-specific resting memory B cells circulate in the blood and can be quantified by their anti-HIV-1 antibody secretion after strong B cell polyclonal stimulation...
- Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cellsAnne Marie Fournier
, Centre Hospitalier et Universitaire, Montpellier, France
Clin Immunol 103:98-109. 2002....
- The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5Yea Lih Lin
Institut de Genetique Humaine, CNRS UPR1142, France
AIDS 22:430-2. 2008..Among the chemokines that bind to CCR5, and induce its internalization, CCL5 is the most abundant in vivo. We show that the level of CCL5 production is a main factor determining CD4+ T cell surface CCR5 density...
- Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapyAntoine Berry
Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Centre Hospitalier Universitaire, 34295 Montpellier Cedex 5, France
Scand J Infect Dis 36:225-7. 2004..The report raises the question whether a rapid immune reconstitution may convert a latent visceral leishmaniasis into a symptomatic one...
- Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimenStephanie Badiou
Department of Biochemistry, University Hospital, Montpellier 34295, France
AIDS 17:772-4. 2003
- Nocardia veterana isolated from ascitic fluid of a patient with human immunodeficiency virus infectionSylvain Godreuil
, , F-34295 Montpellier Cedex 5, France
J Clin Microbiol 41:2768-73. 2003..A phylogenetic analysis was conducted and showed that N. veterana was most closely related to the recently characterized species Nocardia africana rather than to Nocardia vaccinii, as previously reported...
- Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapyJean Marie Bard
Faculte de Pharmacie, Laboratoire de Biochimie, Nantes, France
Antivir Ther 11:361-70. 2006....
- Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general populationMarianne Saves
INSERM U593 ex U330, Universite Victor Segalen Bordeaux 2, Bordeaux, France
Clin Infect Dis 37:292-8. 2003....
- Fulminant varicella hepatitis in a human immunodeficiency virus infected patient: case report and review of the literatureCatherine Lechiche
Infectious and Tropical Diseases Unit, Centre Hospitalier Gui de Chauliac, Montpellier, France
Scand J Infect Dis 38:929-31. 2006..Varicella zoster virus is an uncommon cause of acute liver disease which occurs mainly in immunocompromised patients. Acyclovir is the cornerstone of the treatment...
- Fat microinfiltration autografting for facial restructuring in HIV patientsSophie Domergue
Department of Maxillo-Facial and Oral Surgery, Head: Prof. Dr. P. Goudot, University Hospital of Montpellier, France
J Craniomaxillofac Surg 34:484-8. 2006..CONCLUSION: The results of this procedure after a maximum of 3 years postoperatively have been positive. However, there is a need of long-term experience with this method...
- Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infectionDaniel J Skiest
University of Texas Southwestern Medical Center, Dallas, Texas
Clin Infect Dis 44:607-14. 2007....
- Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latencyIsaure du Chéné
Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, UPR 1142, Montpellier, France
EMBO J 26:424-35. 2007..Finally, we show in different cellular models, including PBMCs from HIV-1-infected donors, that HIV-1 reactivation could be achieved after HP1gamma RNA interference...
- Suppression of microRNA-silencing pathway by HIV-1 during virus replicationRobinson Triboulet
Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, Montpellier, France
Science 315:1579-82. 2007..Our results highlight the involvement of the miRNA-silencing pathway in HIV-1 replication and latency...
- Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adultsStephanie Badiou
Laboratoire de Biochimie des Lipides, Department of Biochemistry, 371 Av du Doyen Gaston Giraud, , CHU Montpellier F34295, France
Atherosclerosis 172:273-9. 2004..CONCLUSION: Fenofibrate therapy improves the atherogenic lipid profile in HIV-positive adults with hypertriglyceridemia...
- Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?Stephanie Badiou
Department of Biochemistry, University Hospital, F34295 Montpellier, France
J Infect 52:335-8. 2006..The aim of our study was to explore the effect of tenofovir on phosphatemia and on tubular phosphate reabsorption...